AHA 2018: AKCEA-APO(a)-LRx - Prof Sotirios Tsimikas

 

Prof Sotirios Tsimikas (University of California, San Diego, US) discusses the safety and efficacy of AKCEA-APO(a)-LRx to lower lipoprotein(a) levels in patients with established cardiovascular disease: A phase 2 dose-ranging trial.

 

Filmed by Radcliffe Cardiology on site at AHA 2018.